Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Nathan Hashimoto

Hospice and Palliative Medicine Long Beach, CA Medical Doctor

NPI 1316998248 CMS profile 59576

2201 N Lakewood Blvd # D629, Long Beach, CA 90815

Open in the dashboard

General payments

$57

3 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Nathan Hashimoto of Long Beach, CA is reported in the CMS Open Payments database as having received $57 across 3 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 34th percentile of Hospice and Palliative Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $21 1
2021 General $11 1
2019 General $25 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nathan Hashimoto
  • Hospice and Palliative Medicine median
  • Middle half of Hospice and Palliative Medicine
  • National median

In program year 2025, general payments to Nathan Hashimoto were reported at $0. Among 151 Hospice and Palliative Medicine profiles paid that year, the median was $79 and the middle half received between $28 and $179.

Show as a table
Year Nathan Hashimoto Hospice and Palliative Medicine median Middle half National median
2019 $25 $70 $20–$164 $163
2020 $0 $67 $19–$171 $114
2021 $11 $81 $22–$170 $132
2022 $21 $92 $29–$229 $149
2023 $0 $98 $33–$185 $160
2024 $0 $68 $24–$170 $164
2025 $0 $79 $28–$179 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Cook Medical LLC $32 2 payments
  2. Novartis Pharmaceuticals Corporation $25 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $57 3 payments
Products named General payments · program years 2019–2022
  1. ENTRESTO $25 1 payment
  2. Torcon NB $21 1 payment
  3. Peel-Away $11 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

445

Median for Hospice and Palliative Care: 260

Drug cost

$18,754

Median for Hospice and Palliative Care: $10,445

Branded share of claims

10.8%

Median for Hospice and Palliative Care: 16.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 22 $13,137
Levothyroxine Sodium Generic 74 $863
Nystop Nystatin Brand 13 $747
Omeprazole Generic 43 $613
Tamsulosin Hcl Generic 25 $520
Atorvastatin Calcium Generic 14 $359
Amlodipine Besylate Generic 33 $288
Famotidine Generic 19 $273
Pantoprazole Sodium Generic 13 $268
Potassium Chloride Generic 18 $223

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,124 Part D prescribers listed as Hospice and Palliative Care; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$3,361

Medicare's payments for the services billed

Medicare patients

24

Average age 77

Services billed

30

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 71%
Diabetes 67%
Heart failure 58%
Ischemic heart disease 50%
Arthritis 46%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

3 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hospice and Palliative Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record